A case report of hemophagocytic lymphohistiocytosis secondary to tislelizumab and bevacizumab combination therapy for renal cell carcinoma
Linli Shi, Xiaobing Li, Rong Xie, Xianmin Zhu et autres
Background: Recently, the widespread application of immune checkpoint inhibitors (ICIs) in the field of tumor therapy has brought clinical benefits to many patients with advanced disease. Simultaneously, immune-related adverse events (irAEs) have attracted growing attention from the academic community. ICI-related hemophagocytic lymphohistiocytosis …
cn, jp (code pays fourni par la source)
1 citation
Translational Cancer Research